You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

1820 Results
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Funding:
Exceptional Access Program
    selpercatinib - For the treatments of advanced or metastatic RET fusion-positive differentiated thyroid carcinoma (DTC); and unresectable advanced or metastatic RET-mutant medullary thyroid cancer (MTC)
Aug 2023
Regimen
Regimen
Cancer Type:
Gynecologic, 
Endometrial, 
Ovary, 
Uterine Sarcoma, 
Vulva, 
Sarcoma, 
Uterine
Intent: Palliative
Nov 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    dexamethasone
Jun 2019
Regimen
Intent: Palliative
Nov 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    ceritinib - Second-line monotherapy of ALK-positive locally advanced (not amenable to curative therapy) or metastatic NSCLC, in patients who have experienced disease progression or intolerance to crizotinib, according to specific criteria
Nov 2021
Regimen
Cancer Type:
Gynecologic, 
Endometrial, 
Ovary
Intent: Adjuvant
Nov 2019
Regimen
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
  • prednisone
Apr 2016
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • buserelin
Oct 2016
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
ODB - General Benefit
    prednisone
Jul 2019
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Aug 2021

Pages